Fundamental analysis · SEC EDGAR · TTM through 31/03/2026
EW · NYSE · Healthcare
Fundamental quality
68
out of 100
Source: SEC EDGAR · TTM through 31/03/2026
The score combines growth, profitability and financial strength. Here its financial strength weighs in its favor, while its growth drags it down the most.
| Year | Revenue | Net income | Free cash flow | Net debt |
|---|---|---|---|---|
| 2021 | $5,233M | $1,503M | $1,406M | -$267M |
| 2022 | $4,464M | $1,522M | $974M | -$173M |
| 2023 | $5,010M | $1,402M | $643M | -$535M |
| 2024 | $5,440M | $4,175M | $290M | -$2,447M |
| 2025 | $6,068M | $1,074M | $1,335M | -$2,340M |
Between 2021 and 2025, revenue went from $5,233M to $6,068M (+16%) and net income went from $1,503M to $1,074M (-29%).
Annual figures in U.S. dollars per SEC filings. Net debt is total debt minus cash.
Is Edwards Lifesciences Corp a profitable company?
Yes. Edwards Lifesciences Corp shows a net margin of 17.4% and an ROE of 10.6%, a sign of a profitable business.
Does Edwards Lifesciences Corp have a lot of debt?
No. Edwards Lifesciences Corp has a net cash position: more cash than debt.
Is Edwards Lifesciences Corp growing?
Its revenue has grown 11.2% annualized in recent years.
Does Edwards Lifesciences Corp generate cash?
Yes. It converts about 17.3% of its revenue into free cash flow.
The thresholds are general and the system doesn't judge qualitative factors. See the full methodology and use this analysis as a first filter, never as a final decision.
Is Edwards Lifesciences Corp cheap or expensive?
That depends on the current price. Look it up, enter it in the tool and get the full valuation verdict (P/E against its sector).
Compute the valuation →Brokers you can use to invest in U.S. and European stocks.
The serious investor's standard →
Popular in the U.S. →
Other analyses
NVIDIA (NVDA) · Microsoft (MSFT) · Apple (AAPL) · Alphabet (Google) (GOOGL) · Amazon (AMZN) · Meta Platforms (META) · see more →